Rob Davis, Merck CEO

February 16, 2022 07:25 AM EST

Hunting deals on all fronts, Merck enlists drug discovery biotech on search for protein modulators

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Lack of detail in Trump's drug price plan raises more questions than answers

Advocacy groups and experts call for decade-long ban on germline editing